
Er-Kim to distribute CNX Therapeutics’ oncology drugs across Europe and Turkey
Ella Day | August 29, 2025 | News story | Logistics & Distribution, Manufacturing and Production, Mergers and Acquisitions | CNX Therapeutics, Corporate, Er-Kim, Oncology, central nervous system disorders, critical care
Turkish pharma company, Er-Kim, has signed a distribution agreement with CNX Therapeutics to expand access to a portfolio of oncology medicines across Central and Eastern Europe (CEE) and Turkey.
The deal includes CNX Therapeutics’ Cardioxane (dexrazoxane) and Savene (dexrazoxane). These two oncology therapeutics that will now be available through Er-Kim’s regional network.
“Er-Kim has been bringing oncology-related medications to emerging European, Middle East and Africa region for over 40 years,” said Mert Zorlular, president and chief financial officer of Er-Kim. “We are always looking for strategic collaborations that enhance our dedication to these markets.”
The move is a significant step in broadening the company’s reach.
“Er-Kim’s regional network across CEE will enable us to access new markets through their distribution infrastructure,” said Pete Butterfield, chief operating officer of CNX Therapeutics.
Founded in Istanbul, Turkey in 1981, Er-Kim works with more than 40 global partners and distributes over 68 products to 50 countries.
Established in 1997 in London, UK, CNX Therapeutics specialises in medicines for oncology, central nervous system disorders and critical care. The company’s products are available in more than 60 markets worldwide.
Ella Day
29/8/25
Related Content

Diurnal joins Er-Kim to distribute cortisol deficiency treatments in Turkey
Diurnal Group, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, has announced …






